Abstract | OBJECTIVES: To investigate whether the immunomodulatory capacities of leflunomide are associated with clinical efficacy in the treatment of primary Sjögren's syndrome (SS) in a phase II pilot study. METHODS: Peripheral blood mononuclear cells from 13 primary SS patients were obtained at baseline and after 24 weeks of leflunomide treatment. Ex-vivo production of interleukin (IL) 1β and tumour necrosis factor α (TNFα) and of interferon (IFN), IL-4, as well as TNFα ELISA measured production on T-cell and monocyte stimulation. In addition, the authors investigated the ability of leflunomide to influence systemic levels of inflammatory cytokines, as well as T-cell activation markers and the expression of IL-7 receptor α by flow cytometry. Correlations between changes in cytokine levels and changes in clinical response parameters were studied. RESULTS: Ex-vivo production of IL-1β and TNFα was decreased at 24 weeks in the whole patient group, whereas IFN and IL-4 production were not significantly changed. However, a significant decrease in T-cell-stimulated IFN and TNFα production was observed in clinical responders, but not in non-responders. Moreover, significant correlations were found between increased sialometry values and decreased IFN and TNFα production. In addition, leflunomide reduced levels of inflammatory serum cytokines and CD40L expression, whereas it upregulated IL-7Rα expression on CD4 T cells with persistent serum IL-7 concentrations. CONCLUSIONS:
Leflunomide treatment suppressed cytokine release from circulating immune cells. Inhibition of T-helper 1 cell cytokine production was related to clinical efficacy. This suggests that selective T-cell targeting might be a relevant therapeutic strategy in primary SS, possibly enhancing clinical efficacy and safety.
|
Authors | Angela Bikker, Jan-Maarten van Woerkom, Aike A Kruize, Kim M G van der Wurff-Jacobs, Johannes W J Bijlsma, Floris P J G Lafeber, Joel A G van Roon |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 71
Issue 12
Pg. 1934-41
(Dec 2012)
ISSN: 1468-2060 [Electronic] England |
PMID | 22563027
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Cytokines
- Isoxazoles
- Receptors, Interleukin-7
- interleukin-7 receptor, alpha chain
- CD40 Ligand
- Leflunomide
|
Topics |
- Adult
- Antirheumatic Agents
(administration & dosage)
- CD4-Positive T-Lymphocytes
(cytology, drug effects, immunology)
- CD40 Ligand
(immunology, metabolism)
- Cells, Cultured
- Cytokines
(blood, immunology)
- Female
- Humans
- Isoxazoles
(administration & dosage)
- Leflunomide
- Middle Aged
- Pilot Projects
- Receptors, Interleukin-7
(immunology, metabolism)
- Sjogren's Syndrome
(drug therapy, immunology)
- Up-Regulation
(drug effects, immunology)
- Young Adult
|